Evaluation of a National Comprehensive Cancer Network Guidelines–Based Decision Support Tool in Patients With Non–Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2020 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2020.9750
Abstract: Key Points Question Is exposure to the National Comprehensive Cancer Center guidelines associated with decreased decisional conflict and increased rates of guideline-concordant care in patients with non–small cell lung cancer? Findings In this nonrandomized clinical… read more here.
Keywords: comprehensive cancer; patients non; national comprehensive; non small ... See more keywords
Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non–Small Cell Lung or Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2021 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.17547
Abstract: Key Points Question What surrogate end point for capturing worsening disease is most correlated with overall survival (OS) in large linked clinicogenomic data sets? Findings In this cohort study of patients with non–small cell lung… read more here.
Keywords: overall survival; end; patients non; non small ... See more keywords
Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.44923
Abstract: This cross-sectional study examines trends in costs of brand-name medications for treatment of non–small cell lung cancer and within-class price differences between these medications in the US from 2015 to 2020. read more here.
Keywords: lung cancer; non small; small cell; 2015 2020 ... See more keywords
Association of Allostatic Load With Overall Mortality Among Patients With Metastatic Non–Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.21626
Abstract: Key Points Question Is there an association among allostatic load (AL), social determinants of health (SDHs), and overall mortality in patients with metastatic non–small cell lung cancer (NSCLC)? Findings In this cross-sectional study of 143… read more here.
Keywords: non small; metastatic non; patients metastatic; overall mortality ... See more keywords
Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non–Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.39874
Abstract: Key Points Question Is overall survival of patients with advanced non–small cell lung cancer (NSCLC) that is estimated from US-based clinical practice data externally valid among Canadian patients who receive the same systemic therapies? Findings… read more here.
Keywords: non small; survival; patients advanced; small cell ... See more keywords
Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non–Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2024 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2024.7542
Abstract: This cohort study evaluates the characteristics, treatment patterns, and outcomes of patients with unresectable stage III non–small cell lung cancer who did or did not receive durvalumab. read more here.
Keywords: stage iii; patients unresectable; non small; small cell ... See more keywords
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non–Small Cell Lung Cancer With or Without Brain Metastases
Sign Up to like & getrecommendations! Published in 2025 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2025.43107
Abstract: This secondary analysis evaluates systemic and intracranial effectiveness and safety of trastuzumab deruxtecan among participants in the DESTINY-Lung01 and DESTINY-Lung02 clinical trials. read more here.
Keywords: non small; mutant metastatic; erbb2 mutant; trastuzumab deruxtecan ... See more keywords
Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases.
Sign Up to like & getrecommendations! Published in 2017 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2017.1047
Abstract: Clinical Question Is up-front whole-brain radiotherapy required to treat multiple brain metastases from non-small-cell lung cancer when highly active targeted therapies are available? Clinical Application Patients with EGFR-mutant or ALK-positive non-small-cell lung cancer with brain… read more here.
Keywords: brain metastases; brain radiotherapy; non small; brain ... See more keywords
Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy
Sign Up to like & getrecommendations! Published in 2021 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2021.1910
Abstract: This randomized clinical trial evaluates the effect of postoperative radiotherapy on survival and safety in patients with pIIIA-N2 non–small cell lung cancer after complete resection and adjuvant chemotherapy. read more here.
Keywords: piiia non; postoperative radiotherapy; non small; effect postoperative ... See more keywords
A Cast of Shadow on Postoperative Radiotherapy for pIIIA-N2 Non-Small Cell Lung Cancer?
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.4442
Abstract: This Viewpoint discusses 2 recent randomized clinical trials evaluating the role of mediastinal postoperative radiotherapy in patients with non–small cell lung cancer. read more here.
Keywords: lung cancer; non small; postoperative radiotherapy; small cell ... See more keywords
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2022.5959
Abstract: This nonrandomized controlled trial evaluates the clinical benefits and safety of atezolizumab plus bevacizumab for treatment of patients with metastatic non–small cell lung cancer (NSCLC) with high tumor mutation burden. read more here.
Keywords: non small; treatment patients; small cell; atezolizumab plus ... See more keywords